In vitro pharmacokinetics of anti-psoriatic fumaric acid esters

BMC Pharmacology

Volumn 4, Issue , 2004, Pages

  Litjens, Nicolle H R ^a   van Strijen, Elizabeth ^a   van Gulpen, Co ^a   Mattie, Herman ^a   van Dissel, Jaap T ^a   Thio, H Bing ^b   Nibbering, Peter H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT; BUFFER; FUMARIC ACID CALCIUM ETHYL ESTER; FUMARIC ACID DERIVATIVE; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID METHYL ESTER; PHOSPHATE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; CITRACONIC ACID; DERMATOLOGICAL AGENT; ESTER; ETHYL FUMARATE; MALEIC ACID DERIVATIVE;

ACIDITY; ALKALINITY; ARTICLE; BLOOD CELL; BLOOD PH; CELL FRACTIONATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG COATING; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; ENTERIC COATED TABLET; ERYTHROCYTE; GRANULOCYTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; MONOCYTE; PSORIASIS; SKIN INFLAMMATION; SMALL INTESTINE; STOMACH PH; TABLET FORMULATION; TIME; BLOOD; HALF LIFE TIME; HYDROLYSIS; METABOLISM; PH; SERUM; STOMACH;

BLOOD CELLS; BUFFERS; DERMATOLOGIC AGENTS; DRUG STABILITY; ESTERS; FUMARATES; HALF-LIFE; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; INTESTINE, SMALL; MALEATES; PSORIASIS; SERUM; STOMACH;

EID: 12944257119     PISSN: 14712210     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2210-4-22     Document Type: Article

References (19)

1. Davison SC, Bunker CB, Basarab T: Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy Br J Dermatol 2002, 147:831-832.
2. Griffiths CE, Clark CM, Chalmers RJ, Li Wan PA, Williams HC: A systematic review of treatments for severe psoriasis. Health Technol Assess 2000, 4:1-125.
3. Koo J, Lee J: Cyclosporine: what clinicians need to know Dermatol Clin 1995, 13:897-907.
4. Kroesen S, Widmer AF, Tyndall A, Hasler P: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003, 42: 17-621.
5. Lebwohl M: Psoriasis. Lancet 2003, 361: 197-1204.
6. Schweckendiek W: Heilung von Psoriasis vulgaris. Med Monatschr 1959, 13:103-104.
7. Schäfer GN: Fumarsäure lindert die Schuppenflechte Selecta 1984, 15:1260-1261.
8. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, Lutz G, Barth J, Rietzschel I, Joshi RK: Antipsoriatic effect of fumaric acid derivates; results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994, 30:977-981.
9. Mrowietz U, Christophers E, Altmeyer P: Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998, 138: 56-460.
10. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D: Fumaric acid therapy for psoriasis: a randomized, doubleblind, placebo-controlled study. J Am Acad Dermatol 1990, 22: 11-312.
11. Thio HB, van der Schroeff JG, Nugteren-Huying WM, Vermeer BJ: Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis. J Eur Acad Dermatol Venereol 1995, 4:35-40.
12. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN: Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003, 149:363-369.
13. Mrowietz U, Christophers E, Altmeyer P: Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999, 141:424-429.
14. Litjens NHR, Nibbering PH, Barrois AJ, Zomerdijk TPL, Oudenrijn van den AC, Noz KC, Rademaker M, van de Meide PH, van Dissel JT, Thio B: Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type-1 cytokines. Br J Dermatol 2003, 148:444-451.
15. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P: Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos 2003, 24:259-273.
16. Litjens NHR, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, van Dissel JT, Thio HB, Nibbering PH: Pharmacokinetics of oral fumarates in healthy subjects. Brit J Clin Pharmacol 2004, 58:429-432.
17. Nibbering PH, Thio HB, Zomerdijk TPL, Bezemer AC, Beijersbergen RL, van Furth R: Effects of monomethylfumarate on human granulocytes. J Invest Dermatol 1993, 101:37-42.
18. De Jong R, Bezemer AC, Zomeredijk TPL, van de Pouw-Kraan T, Ottenhoff THM, Nibbering PH: Selective stimulation of T helper 2 cytokine responses by the antipsoriasis agent monomethyl-fumarate on human granulocytes. Eur J immunol 1996, 26:2067-2074.
19. Litjens NHR, Rademaker M, Ravensbergen B, Rea D, van der Plas MJA, Thio B, Walding A, van Dissel JT, Nibbering PH: Monomethyl-fumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 2004, 34:565-575.